INTERFERON AND AFINITOR, A POTENTIAL COMBINATION FOR TRIPPLE NEGATIVE BREAST CANCER.

In a recent report about the genome of triple Negative Breast Cancer, researchers reported that there are 3 genes discovered at greater the 10% in this disease.  One of which was STAT1.  In a discussion with Reporters, DR Baumback-Reardon reported "one of the genes down regulated in the Kenyan tumors (with triple negative Breast cancers), STAT1 , is especially noteworthy in that it is has tumor suppression and immune regulating activity".   Interferon has these 2 abilities combined just perfectly.
The Mammallian Target of Rapamycin (mTor) which affect Mitochondrial function are known to affect STAT1.  It would be of Interest to see if this combination of Interferon alpha would be useful to stop Breast Cancer of triple negative nature in its track.
Adding Afinitor to exametestane has already proven a rescue option in patient AI refractory disease
but science is pushing us to believe Afinitor has a long way helping in other areas!

IS STAT1 EXPRESSION A DRIVER GENOME VARIABLE IN TRIPLE NEGATIVE BREAST CANCER?  

IT IS ALSO KNOWN THAT MTOR INHIBITOR HAVE ACTIVITY IN BRAC-1 CELL TUMORS WHICH IS 85% OF TRIPLE NEGATIVE  BREAST CANCER  IN SOME REPORTS